



*H2020-NMBP-TR-IND-2020-twostage  
Next generation organ-on-chip (RIA-LS)*

## **Tumor-LN-oC**

**Tumor and Lymph Node on Chip for cancer studies**

Starting date of the project: 01/05/2021

Duration: 48 months

---

### **= Deliverable D17.1 =**

#### **Dissemination and communication activities - Period A**

Due date of deliverable: 30/04/2023

Actual submission date: 30/04/2023

Responsible WP: Kristin Aldag, AMI

Responsible TL: Kristin Aldag, AMI

Revision: V1.0

<b>Dissemination level</b>		
PU	Public	X
PP	Restricted to other programme participants (including the Commission Services)	
RE	Restricted to a group specified by the consortium (including the Commission Services)	
CO	Confidential, only for members of the consortium (including the Commission Services)	



*This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 953234.*

**AUTHOR**

Author	Institution	Contact (e-mail, phone)
Kristin Aldag	AMI	<a href="mailto:aldag@amires.eu">aldag@amires.eu</a>
All partners contributing		

**DOCUMENT HISTORY**

Document version	Date	Change
0.1	15.04.2023	Pre-final draft sent to consortium
0.2	20.04.2023	Final version sent to consortium
1.0	28.04.2023	Final version

**VALIDATION**

Reviewers	Validation date	Name
Work Package Leader	28.04.2023	Kristin Aldag, AMI
Project Manager	28.04.2023	Kristin Aldag, AMI
Coordinator	20.04.2023	Ioanna Zergioti, ICCS

**DOCUMENT DATA**

<b>Keywords</b>	Dissemination, Communication
<b>Point of Contact</b>	Name: Kristin Aldag Partner: AMI Address: Na Okraji 335/42, 162 00 Praha 6 Phone: +420 603 334 830 E-mail: <a href="mailto:aldag@amires.eu">aldag@amires.eu</a>
<b>Delivery date</b>	30.04.2023

**DISTRIBUTION LIST**

Date	Issue	Recipients
19.04.2023	V0.1	Partners via email
30.04.2023	V1.0	Partners via OwnCloud, Commission via portal

**DISCLAIMER**

Any dissemination of results reflects only the authors' view and the European Commission Horizon 2020 is not responsible for any use that may be made of the information Deliverable D17.1 contains.

## Executive Summary

This Deliverable reports on T17.1, “Implementation of high impact dissemination and communication activities – Period A”. The task involved the design and production of the Tumor-LN-oC promotional materials, representation on the project website and through social media pages as well as the Tumor-LN-oC presence in conferences and other event, the dissemination of results in scientific/ technical journals, magazines and blogs. This document is a working document outlining the dissemination activities for the project’s first period (M1-M24), the task will be seamlessly continued in T18.1 (M24 – M48).

## Table of Contents

<b>1. Introduction</b>	<b>5</b>
<b>2. Report on dissemination activities</b>	<b>5</b>
2.1. Role of Dissemination manager	5
2.2. Tumor-LN-oC Dissemination materials	5
2.3. Templates	8
2.4. Project Website	9
2.4.1. Overview	9
2.4.2. Website analytics	10
<b>3. Social media</b>	<b>12</b>
3.1.1. Twitter	12
3.1.2. LinkedIn	14
3.2. Graphics	15
3.3. Events and conferences	16
3.4. Scientific Publications	21
3.5. Clustering and engagement with other projects	22
<b>4. Review of project dissemination strategy</b>	<b>23</b>
<b>5. Conclusions</b>	<b>23</b>
<b>6. Degree of Progress</b>	<b>23</b>
<b>7. Dissemination level</b>	<b>23</b>

## Table of figures

Figure 1: Tumor-LN-oC Dissemination materials available for download on the project website .....	6
Figure 2: Project leaflet.....	7
Figure 3: Project presentation .....	7
Figure 4: Tumor-LN-oC Roll-Up Design (pending printing) .....	8
Figure 5: Internal PowerPoint Template, e.g. for project meetings .....	9
Figure 6: Tumor-LN-oC Website.....	9
Figure 7: "About" page.....	10
Figure 8: News and events section on the website .....	10
Figure 9: Tumor-LN-oC Website statistics 01.11.2021 - 17.04.2023 (M6-M24).....	11
Figure 10: Location of website users 01.05.2021 - 17.04.2023 (M1-M24).....	11
Figure 11: Top pages viewed 01.05.2021 - 17.04.2023 (M1-M24).....	11
Figure 12: Acquisition of users, 01.05.2021 - 17.04.2023 (M1-M24) .....	12
Figure 13: New vs. returning users 01.05.2021 - 17.04.2023 (M1-M24).....	12
Figure 14: Tumor-LN-oC Twitter page .....	13
Figure 15: Sample tweet .....	14
Figure 16:Tumor-LN-oC LinkedIn Page .....	15
Figure 17: Sample LinkedIn post.....	15
Figure 18: Template for social media posts on Canva .....	15
Figure 19: LinkedIn Post announcing Tumor-LN-oC participation at IndTech 2022 in Grenoble (June 2022) .....	17
Figure 20: Twitter Post announcing Tumor-LN-oC participation at Nanotextology 2022 .....	17
Figure 21: Tumor-LN-oC community on Zenodo .....	21
Figure 22: Procedure outlined in article 8.4.2 of the consortium agreement.....	22

## List of tables

Table 1. Tumor-LN-oC Dissemination materials .....	6
Table 2: Website analytics – M1-M24 vs. M19-M24 (via Google Analytics) .....	11
Table 3: List of Tumor-LN-oC Twitter posts .....	13
Table 4: Overview of Tumor-LN-oC LinkedIn posts .....	14
Table 5: List of identified relevant conferences and events.....	16
Table 6: Participation in events and conferences.....	18
Table 7: Participation in events and conferences confirmed for 2023 and 2024.....	20
Table 8: Overview of Tumor-LN-oC scientific publications.....	21
Table 9: Clustering with other EU project.....	22

## 1. Introduction

This Deliverable reports on T17.1, “Implementation of high impact dissemination and communication activities – Period A. Through this Task, the consortium, led by partner AMIRES, has implemented the communication and dissemination strategy and associated activities between M7-M24. The Task involved the design and production of the Tumor-LN-oC promotional, written and audio-visual digital materials (brochures, leaflets, newsletters and videos), as well as the coordination of Tumor-LN-oC presence in dissemination fora, such as conferences and events. Dissemination of results also included the publication of articles in scientific/ technical journals, magazines and blogs which, due to the nature of the project and subject matter, has been limited during the first half of the project. Through the task, Tumor-LN-oC was be represented through social media pages (i.e. LinkedIn) for easier access to larger audiences and industrial end users. At the same time, these bi-directional communication platforms are excellent means to receive feedback from the users’ community, citizens, and Tumor-LN-oC -related organisations. Collaboration was also sought between the other active H2020 projects and Tumor- LN-oC will get in contact with other coordinators to exchange relevant project related information and invite each other to specific events.

## 2. Report on dissemination activities

### 2.1. Role of Dissemination manager

While all project partners are committed to communicate and disseminate project results, the dissemination manager role was created in order to ensure the dissemination obligations are met and the project generates the greatest possible reach and engages with stakeholders. The dissemination manager role is held by Kristin Aldag (AMIRES). Main roles and responsibilities of the dissemination manager include:

- Provision of printed or digital dissemination material to partners according to project visual identity
- Regular update posts and general maintenance of project website and social media channels
- Coordination, monitoring and reporting of consortium dissemination activities, such as event/conference participation and scientific publications
- Initial reaction to any external enquiries, e.g. via the contact form on the website, in close cooperation with the coordinator
- Ensuring flow of information between project partners
- Design and distribution of internal templates (e.g. presentations, deliverables, reports)
- Support to partners in all matters related to dissemination (e.g. event organisation or participation, website & social media, open access)
- Curating the Tumor-LN-oC Zenodo community


### 2.2. Tumor-LN-oC Dissemination materials

A core element of task 17.1 is the design and production of the Tumor-LN-oC promotional, written and audio-visual digital materials (brochures, leaflets, newsletters and videos). As already presented in the M18 report, Tumor-LN-oC partners have at their disposal a range of project dissemination materials (see Table 1).

Further material, e.g. posters, videos and press releases will be prepared and published once more project results are ready to be presented to the public and intellectual property considerations are advanced. All public materials can be downloaded from the project website (see Figure 1).

Table 1. Tumor-LN-oC Dissemination materials

Type	Status	Link
Logo	Summer 2021, no updates necessary	<a href="https://tumor-ln-oc.eu/wp-content/uploads/2021/08/TUMOR_logo.svg">https://tumor-ln-oc.eu/wp-content/uploads/2021/08/TUMOR_logo.svg</a>
Initial press release	02.09.2021, no updates necessary	<a href="https://tumor-ln-oc.eu/wp-content/uploads/2021/09/Tumor-LN-oC-press-release_KA.pdf">https://tumor-ln-oc.eu/wp-content/uploads/2021/09/Tumor-LN-oC-press-release_KA.pdf</a>
Factsheet	30.09.2021, no updates necessary	<a href="https://tumor-ln-oc.eu/wp-content/uploads/2021/09/Tumor-LN-oC_bullet-point-summary.pdf">https://tumor-ln-oc.eu/wp-content/uploads/2021/09/Tumor-LN-oC_bullet-point-summary.pdf</a>
Leaflet	01.05.2022, no updates necessary	<a href="https://tumor-ln-oc.eu/wp-content/uploads/2022/05/TUMOR_leaflet_1.0.pdf">https://tumor-ln-oc.eu/wp-content/uploads/2022/05/TUMOR_leaflet_1.0.pdf</a>
Presentation	15.07.2022, pending update on project progress	<a href="https://tumor-ln-oc.eu/wp-content/uploads/2023/04/Tumor-LN-oC_general-presentation_v1.0.pdf">https://tumor-ln-oc.eu/wp-content/uploads/2023/04/Tumor-LN-oC_general-presentation_v1.0.pdf</a>
Roll-Up	17.04.2023	<a href="https://owncloud.amires.eu/index.php/s/hQfWVGFnLE2KSAp">https://owncloud.amires.eu/index.php/s/hQfWVGFnLE2KSAp</a>



**TUMOR LN-oC**

ABOUT TUMOR-LN-OC PROJECT TEAM NEWS & EVENTS DISSEMINATION MATERIALS

## DISSEMINATION MATERIALS

Tumor-LN-oC latest achievements, technical results and scientific outputs will be published in this section as well as on the [Tumor-LN-oC community](#) on Zenodo.

**SCIENTIFIC PUBLICATIONS**

Soto Veliz, D., Lin, K. L., & Sahlgren, C. (2023). Organ-on-a-chip technologies for biomedical research and drug development: A focus on the vasculature. *Smart Medicine*, 2(1), e20220030. <https://doi.org/10.1002/SMMD.20220030>. [Download PDF](#)

Chiara, M. A., Elezoglou, S., & Zergioti, I. (2022). Bioprinting on Organ-on-Chip: Development and Applications. *Biosensors*, 12(12), 1135. <https://doi.org/10.3390/bios12121135>. [Download PDF](#)

To stay up to date on any new publications, check out our community on [Zenodo!](#)

**PUBLIC DELIVERABLES**

**Project website launch** – The document describes the creation of a comprehensive dedicated website for the project. This was established at the beginning of the project and set up for public access. The website will be actively maintained during the project period.

**Dissemination plan** – This deliverable outlines the main elements and strategic choices regarding the dissemination and communication activities of the Tumor-LN-oC project towards the most important stakeholder groups.

**PRESS RELEASES**

**First Press Release** – After the project kicked off in May 2021, the Tumor-LN-oC consortium published the project's first press release on September 7th, 2021. It contains more information on the launch of the project, as well as its objectives and expected impact.

**DOWNLOADS**

**Factsheet/One-Pager** – The factsheet provides general project information, a description of the Tumor-LN-oC ambition and expected impact as well as information on partners and project contacts.

**Leaflet** – The leaflet informs about the project context and its objectives

**Project Presentation** – The presentation gives an overview over the project consortium and introduces the project objectives, technological modules to be developed and overall concept in more depth, as well as expected results and anticipated impact.

Figure 1: Tumor-LN-oC Dissemination materials available for download on the project website

Tumor-LN-oC



The EU-funded Tumor-LN-oC project is developing a tumor-lymph node on-chip platform which will mimic the tumor microenvironment and its connection to the lymphatic system. The multidisciplinary microfluidic platform will make it possible to monitor the lymph node metastasis process, characterise signalling cues facilitating such metastasis, and identify spectral and molecular signatures in metastasizing cells. This makes Tumor-LN-oC a breakthrough innovation in metastasis diagnosis and drug testing.



OBJECTIVES

- Generate a Tumor-LN-oC multidisciplinary microfluidic platform, optimized for tumor cell and lymph culture and enabling the study of their crosstalk
- Monitor in real time the cell migration with a beyond state-of-the-art micro-optics module and an advanced image analysis platform
- Integrate Quantum Cascade Lasers (QCL) based mid-IR photothermal (MIP) spectroscopy for specific chemical signatures
- Molecularly characterize migrating tumor-derived cells attracted to the LN, and the soluble signals driving migration
- Integrate all Tumor-LN-oC technologies in an automated platform prototype incorporating interfaces compatible with existing laboratory equipment
- Validate the Tumor-LN-oC platform with real lung cancer patient samples
- Establish regulatory pathways and assure compliance with regulatory requirements for exploitation and early market entry

**BASIC FACTS**

**Title** Tumor and Lymph Node on Chip for cancer studies

**Acronym** Tumor-LN-oC

**Project Coordinator** Prof. Ioanna Zergioti  
Institute of Communication and Computer Systems  
National Technical University of Athens, Greece  
zergioti@mail.ntua.gr

**Project Manager** Kristin Aldag  
Amires s.r.o.  
Prague, Czech Republic  
aldag@amires.eu

**WHO WE ARE**

**TUOR LN-oC**

www.tumor-ln-oC.eu

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 953234, project Tumor-LN-oC.

Figure 2: Project leaflet

**1. TUOR LN-oC Tumor and Lymph Node on Chip for cancer studies**

**2. The Project**

**3. The consortium**

**4. Project summary**

**5. Project objectives**

**6. 6 technological modules**

**7. Project Concept**

**8. Project impact**

**9. Expected results**

**10. Project progress**

**11. Get in touch!**

**12. Thank you! Any questions?**


Figure 3: Project presentation

## Tumor-LN-oC



**T U M O R**  
LN - oC

**TUMOR AND LYMPH NODE ON CHIP FOR CANCER STUDIES**  
WWW.TUMOR-LN-OC.EU


Individual platforms	System Integration	Preclinical Validation	Exploitation
			
			
			

**TECHNOLOGICAL MODULES**

- Microfluidic chip optimized for tumor cell and LN culture, enabling the study of their crosstalk
- Perfusion platform with peripheral components, featuring validated flow control
- Real time image analysis via micro-optics module for detection of metastasising cells
- MIP spectroscopic sensor for rapid cell recognition and analysis
- Signal processing platform via deep learning algorithms
- Laser bioprinting of tumor and LN cell lines
- Integration into an automated microfluidic platform, compatible with existing laboratory equipment

**APPLICATION AREAS**

- Metastasis detection and monitoring
- Drug development and personalised medicine


WWW.TUMOR-LN-OC.EU

Co-funded by the European Union

THIS PROJECT HAS RECEIVED FUNDING FROM THE EUROPEAN UNION'S HORIZON AND ASSISTANCE FOR GROWTH AND EMPLOYMENT UNDER GRANT AGREEMENT NO. 101019744. PROJECT: TUMOR-LN-OC

Figure 4: Tumor-LN-oC Roll-Up Design (pending printing)

### 2.3. Templates

In addition to external visual materials, project partners have access to internal templates for presentations, deliverables, reports and any other necessary documents in the Tumor-LN-oC design. They are available anytime on the OwnCloud Filesharing platform. In addition, updated templates are shared prior to any project meeting.



## Tumor-LN-oC




Figure 5: Internal PowerPoint Template, e.g. for project meetings

## 2.4. Project Website

### 2.4.1. Overview

The Tumor-LN-oC website is available at <https://tumor-ln-oc.eu/>

The website provides interested public with all basic information about the project, such as the objectives, impact and results, as well as the project consortium. The website is regularly updated with any news (see Figure 8). In addition, all dissemination materials, public deliverables and scientific publications are available for download (see Figure 1). The website is hosted on the WordPress platform and easily updated and maintained by the dissemination manager. The website also links to the Twitter and LinkedIn Page and offers a contact form which is redirected to the dissemination manager who forwards any relevant inquiries to the coordinator.




Figure 6: Tumor-LN-oC Website




Figure 7: "About" page



Figure 8: News and events section on the website

### 2.4.2. Website analytics

Google Analytics tools provides insight on relevant data, e.g. how many times the website has been visited and where users are located. Overall, since the beginning for the project, over 850 users have visited the website and the pages have been viewed a total of 2530 times. On average, users visit 2.12 pages per session and spend 1:35 minutes on a page (see Table 2). During the most recent M19-M24 period, the traffic has been rather low (see Figure 9,

Table 2), which will be attempted to be increased in coming months by more active posting and sharing.

Tumor-LN-oC




Figure 9: Tumor-LN-oC Website statistics 01.11.2021 - 17.04.2023 (M6-M24)

Table 2: Website analytics – M1-M24 vs. M19-M24 (via Google Analytics)

Category	M1-M24	M19-M24
	01.05.2021 – 17.04.2023	01.10.2022 – 17.04.2023
<b>Users</b>	850	83
<b>Page views</b>	2530 (2096 unique)	392 (320 unique)
<b>Sessions</b>	1194	152
<b>Pages per session</b>	2.12	2.58
<b>Sessions per user</b>	1.4	2.83
<b>Average time on page</b>	1:35 min	1:29 min
<b>Average session duration</b>	1:47 min	2:22 min
<b>New visitor vs returning visitor</b>	850 new (88.8%) 107 returning (11.2%)	82 new (75.9%) 26 returning (24.1%)

Nevertheless, the global reach is quite good with over 150 users visiting the site from the US and even 27 users from China (see Figure 10). Countries in which Tumor-LN-oC partners are located are most represented.

Not surprisingly, the homepage is the most visited page, followed by the consortium page, “about” page, news and events page, dissemination material page and contact page (see ).

Country	Users	% Users
1.  United States	159	18.30%
2.  Netherlands	130	14.96%
3.  Finland	112	12.89%
4.  Greece	83	9.55%
5.  France	52	5.98%
6.  Austria	50	5.75%
7.  Czechia	45	5.18%
8.  United Kingdom	40	4.60%
9.  China	27	3.11%
10.  Germany	25	2.88%

Figure 10: Location of website users 01.05.2021 - 17.04.2023 (M1-M24)

Page	Page Views	% Page Views
1. /	1,058	41.82%
2. /project-team/	425	16.80%
3. /about/	315	12.45%
4. /news-events/	202	7.98%
5. /dissemination-materials/	164	6.48%
6. /contacts/	94	3.72%
7. /tumor-ln-oc-project-has-kicked-off/	58	2.29%
8. /questionnaire-for-end-users/	45	1.78%
9. /tumor-ln-ocs-first-pres-release/	42	1.66%
10. /6-months-completed/	29	1.15%

Figure 11: Top pages viewed 01.05.2021 - 17.04.2023 (M1-M24)

## Tumor-LN-oC




Figure 12: Acquisition of users, 01.05.2021 - 17.04.2023 (M1-M24)

When it comes to acquisition of users to the Tumor-LN-oC website, or in other words ways people find the site, following results were achieved during M1-M24:

- 584 users visited the website directly, such as typing the website's URL directly into their browser
- 166 users came from organic search (unpaid listings on Google and other search engine results pages)
- 73 users came via a referral - Traffic from links to Tumor-LN-oC website on other websites
- 67 users came from social media platforms, which includes LinkedIn and Twitter

■ New Visitor ■ Returning Visitor




Figure 13: New vs. returning users 01.05.2021 - 17.04.2023 (M1-M24)

The vast majority of website users are new visitors, meaning many people only visit once and don't come back to check for any updates. Ways to increase user retention will be explored and partners will be regularly reminded to share project news on their own channels in order to drive more traffic to the Tumor-LN-oC website.

### 3. Social media

Tumor-LN-oC representation through social media pages (i.e. LinkedIn, Twitter) is a great way to allow for easier communication with to larger audiences, the general public and industrial end users. At the same time, these bi-directional communication platforms are an excellent means to receive feedback from the users' community, citizens and stay up to date on Tumor-LN-oC-related undertakings. Short news stories about the Tumor-LN-oC project and its development are prepared and shared on the especially during events, conferences, and symposiums.

Dedicated pages were created for the Tumor-LN-oC project on LinkedIn and Twitter, which are considered the best way to reach and engage with the identified target audiences (scientific community, industry stakeholders, policy makers). In addition, partners are encouraged to share and post on their own channels about the project.

#### 3.1.1. Twitter

The Tumor-LN-oC Twitter account is used to share any news and updated, real-time information about the project. Dissemination manager from AMIRES is account owner and responsible for regular post updates. All partners are encouraged to share any news and project results to be posted and regularly reminded of this possibility.

However, after ca. 1.5 years and over 25 posts, the Tumor-LN-oC twitter page has only 29 followers. In addition, as shown in Table 3, the reach and engagement with posts is rather low, so while the page will continue to be regularly updated and outreach will be attempted to be improved, other channels such as LinkedIn, where project partners are more active and re-sharing the information, will be prioritised to ensure that the content reaches identified target audiences.

## Tumor-LN-oC

Table 3: List of Tumor-LN-oC Twitter posts

#	Post topic	Date	Impressions	Engagement	Likes	Retweets	URL
1	Intro	11/01/2022	65	6	2	1	https://twitt
2	End-User questionnaire	13/01/2022	239	24	2	2	https://twitt
3	End-User questionnaire 2	17/01/2022	136	9	3	2	https://twitt
4	End-User questionnaire EURO	31/01/2022	122	4	1	1	https://twitt
5	International Day of Women a	11/02/2022	121	4	2	1	https://twitt
6	Partner ICCS	10/03/2022	51	2	0	0	https://twitt
7	Partner TU/e	16/03/2022	51	2	0	0	https://twitt
8	Partner BRFAA	18/03/2022	156	10	3	1	https://twitt
9	Partner AAU	22/03/2022	210	7	3	0	https://twitt
10	Partner Alpes	24/03/2022	111	3	2	1	https://twitt
11	SPIE Intro	28/03/2022	426	7	3	2	https://twitt
12	SPIE report	12/04/2022	99	8	3	0	https://twitt
13	World Health Day	19/04/2022	200	18	8	2	https://twitt
14	M12 Meeting	13/05/2022	517	24	9	5	https://twitt
15	IndTech 1	28/06/2022	88	9	5	0	https://twitt
16	IndTech 2	29/06/2022	199	11	3	2	https://twitt
17	ICCS + TU/e at Euroocs Grei	07/07/2022	174	8	2	0	https://twitt
18	TUW at ICPPP21	11/07/2022	23	2	1	0	https://twitt
19	RegMed invitation	15/07/2022	20	0	0	0	https://twitt
20	RegMed invitation 2	20/07/2022	25	1	0	0	https://twitt
21	Phos Print at Nanotexnology	25/07/2022	78	4	2	1	https://twitt
22	RegMed event	17/10/2022	61	15	6	2	https://twitt
23	M18 project + review meeting	30/11/2022	146	13	5	2	https://twitt
24	PhosPrint selected as finalisz	12/12/2022	66	7	3	1	https://twitt
25	World Cancer Day	06/02/2023	44	3	2	1	https://twitt
26	World Health day (retweet fr	18/04/2023	3	0	0	0	https://twitt
<b>27</b>	<b>Status 18.04.2023</b>	<b>29</b>	<b>3431</b>	<b>201</b>	<b>70</b>	<b>27</b>	
Posts		Followers	Impressions	Engagement	Likes	Retweets	

**Tumor and Lymph Node on Chip for cancer studies**

**T U LN-oC R**

ALPES LASERS PhosPrint TU/e RIVM ASPHALION AMIRIS

**Tumor-LN-oC**  
@Tumor\_LN\_oC

#Horizon2020 funded project "Tumor and Lymph Node on Chip for cancer studies" (GA No 953234)

tumor-ln-oc.eu Joined December 2021

32 Following 29 Followers

Figure 14: Tumor-LN-oC Twitter page

## Tumor-LN-oC



Figure 15: Sample tweet

## 3.1.2. LinkedIn

Similar to Twitter, the Tumor-LN-oC LinkedIn account is used to share any news and updated, real-time information about the project. The account is maintained and updated by the dissemination manager.

As seen in Table 4, LinkedIn seems to have a better reach than Twitter, as consortium partners are more active on their own LinkedIn accounts (team members) and pages (partner organisations) and are actively engaging with and cross-sharing any news posts, which leads to more overall engagements. As of April 2023, Tumor-LN-oC project has 83 followers on LinkedIn and overall more than 6500 views of the 15 posts made, which is a satisfying result.

Table 4: Overview of Tumor-LN-oC LinkedIn posts

Nr.	Post topic	Date	Impressions	Unique impressions	Engagements	Reposts	Reactions	Comments	Clicks
1	End-User questionnaire	17/01/2022	229	71	22	3	7	0	12
2	End-User questionnaire EUROoCS	01/02/2022	434	241	38	3	13	0	22
3	2nd Milestone	28/03/2022	428	254	41	0	12	0	29
4	PhosPrint at SPIE	12/04/2022	148	44	8	3	1	0	4
5	World Health Day HaDEA	19/04/2022	120	52	10	0	4	0	6
6	M12 Meeting	20/05/2022	1782	1143	115	0	33	0	82
7	IndTech	01/07/2022	983	561	82	0	29	1	52
8	RedMed invite	20/07/2022	201	123	13	0	6	0	7
9	RedMed invite 2 (repost from AMIRES)	03/10/2022	58	34	5	0	4	0	1
10	RedMed invite 3 (repost from AMIRES)	11/10/2022	38	22	0	0	0	0	0
11	RegMed report	19/10/2022	700	470	54	1	23	1	29
12	M18 project and review meeting	30/11/2022	1116	841	48	4	24	0	20
13	PhosPrint selected as finalist at SPIE St	12/12/2022	54	38	7	0	6	0	7
14	PhosPrint 3rd place at SPIE Startup char	08/02/2023	105	72	11	0	8	1	11
15	World Health Day HaDEA	12/04/2023	197	148	13	0	8	0	5
15	Status 18.04.2023	83	6593	4114	467	14	178	3	244
Posts		Followers	Impressions	Unique impressions	Engagement	Reposts	Reactions	Comments	Clicks




Figure 16: Tumor-LN-oC LinkedIn Page




Figure 17: Sample LinkedIn post

### 3.2. Graphics

Graphical content for the social media is prepared by the dissemination manager on Canva. Templates have been created in order to ensure coherent visual appearance.




Figure 18: Template for social media posts on Canva

### 3.3. Events and conferences

Attendance of events and conferences is one of the main ways in which Tumor-LN-oC partners engage with the scientific community beyond the project, make connections with other stakeholders, disseminate project results and gather relevant feedback. Relevant conferences and target audiences were identified in the Dissemination Strategy (D16.2) and continue to be relevant. This includes the :

*Table 5: List of identified relevant conferences and events*

Scientific conferences	Exhibitions / industry events
<ul style="list-style-type: none"> <li>• MicroTas- International Conference on Miniaturized Systems for Chemistry and Life Sciences</li> <li>• SelectBio</li> <li>• SciX</li> <li>• EMRS meetings</li> <li>• International Conference on Advanced Vibrational Spectroscopy (ICAVS)</li> <li>• SPIE photonics</li> <li>• International Conference on Biosensing Technology</li> <li>• EOS conference in opto-fluidics, World Congress on Biosensors</li> <li>• Gordon Research Conferences</li> <li>• EMBO and EMBL conferences and workshops</li> <li>• EUROoCS annual conferences</li> </ul>	<ul style="list-style-type: none"> <li>• BioChip Berlin,</li> <li>• SELECTBIO Organ-on-a-Chip</li> <li>• SPIE Photonics West,</li> <li>• SPIE Photonics Europe,</li> <li>• European Materials Research Society (EMRS)</li> <li>• CLEO Conference,</li> <li>• International Conference on Biomedical Imaging,</li> <li>• Signal Processing (ICBSP)</li> <li>• International Conference on Biomedical Engineering and Bioinformatics (ICBEB)</li> <li>• IPhEB Russia,</li> <li>• Rommedica,</li> <li>• Medicine and Health,</li> <li>• Swiss Medtech Expo,</li> <li>• Compamed</li> </ul>

The consortium is very active in this respect and regularly participating in many events to present the project, disseminate its results, and network with other research, industry representatives and stakeholders (see Table 6).

The Dissemination manager is informing the consortium about any identified events, coordinating the Tumor-LN-oC presence, providing dissemination materials and encouraging follow-up with relevant contacts made. In addition, information about all dissemination activities including conference participation is regularly gathered during the internal reporting which takes place every 6 months. News about any significant conference participation is shared on the Tumor-LN-oC website and Social Media (see Figure 19 and Figure 20).



## Tumor-LN-oC

 **Tumor-LN-oC**  
85 followers  
10mo • 🌐

#Organonchip, #microfluidics, #bioprinting and other modules of the Tumor-LN-oC #platform are promising technologies for the #health and #pharma industry as well as #personalisedmedicine.

To achieve the desired #impact and #objectives, the #TumorLNOC consortium is eager to #network and engage with #partners and #stakeholders from various industries.

📅 That's why we were happy to participate in #IndTech2022 in Grenoble this week! 🇫🇷

Coordinator **Ioanna Zergioti** and project manager **Kristin Aldag** represented the project, answered questions and passed out leaflets around the conference and at the booth of our partner **AMIRES**.

Visit our Website to learn more about the project! ➡ <https://tumor-ln-oc.eu/>



Learn more at [www.tumor-ln-oc.eu](http://www.tumor-ln-oc.eu)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 953234, project Tumor-LN-oC

Figure 19: LinkedIn Post announcing Tumor-LN-oC participation at IndTech 2022 in Grenoble (June 2022)

 **Tumor-LN-oC @Tumor\_LN\_oC** · Jul 25, 2022

Were you at @NANOTECHNOLOGY\_2022? 🌟

Hopefully you had a chance to listen to the presentation by #TumorLNOC member Evina Elezoglou from #PhosPrint about 3D #Bioprinting of #cancer cells and tumor #organoids for #organonchip applications! 🇫🇷

Congrats on the successful talk 🌟



Learn more at [www.tumor-ln-oc.eu](http://www.tumor-ln-oc.eu)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 953234, project Tumor-LN-oC

Figure 20: Twitter Post announcing Tumor-LN-oC participation at Nanotextology 2022

## Tumor-LN-oC

Table 6: Participation in events and conferences

Conference Name	Date	Location	Responsible Partner	Tumor-LN-oC participation	Link
<b>2021</b>					
<b>Webinar, organised by Medical school of the National % Kapodistrian University of Athens</b>	08.10.2021	Online	ICCS: Ioanna Zergioti	Presentation	
<b>Career in STEM</b>	21.10.2021	University of Bern	ICCS: Ioanna Zergioti	Keynote lecture	
<b>I3D21- Nanotexnology</b>	07.-08.07.2021	Thessaloniki, Greece	ICCS: Ioanna Zergioti	Invited talk	<a href="https://www.nanotexnology.com/2021/">https://www.nanotexnology.com/2021/</a>
<b>ASAC Meeting: "Next-Generation Analytical Chemists"</b>	26.11.2021	Vienna/Online	TUW		<a href="https://anchem.univie.ac.at/vortraege-lehrveranstaltungen/asac-2021/">https://anchem.univie.ac.at/vortraege-lehrveranstaltungen/asac-2021/</a>
<b>30th Biocity Symposium / 14th Finnish Cancer Institute Symposium: Cancer – Breaking bad</b>	19.-20.08.2021	Turku, Finland	AAU		<a href="https://www.biocimaging.fi/30th-biocity-symposium-register-now/">https://www.biocimaging.fi/30th-biocity-symposium-register-now/</a>
<b>Joint Nordic Matrix Biology Meeting</b>	03.-04.11.2021	Oulu, Finland	AAU		<a href="https://www.sidekudostutkijat.fi/arkisto/the-joint-nordic-matrix-biology-meeting">https://www.sidekudostutkijat.fi/arkisto/the-joint-nordic-matrix-biology-meeting</a>
<b>2022</b>					
<b>SPIE Photonics West</b>	22.-27.01.2022	San Francisco/remote	TUW, ICCS		<a href="https://spie.org/conferences-and-exhibitions/photonics-west">https://spie.org/conferences-and-exhibitions/photonics-west</a>
<b>Spring SciX</b>	11.-14.04.2022	Liverpool	TUW		<a href="https://www.springscix.org/">https://www.springscix.org/</a>
<b>SPIE Photonics Europe</b>	03.-07.04.2022	Strasbourg	PhosPrint: Evina Elezoglou		<a href="https://spie.org/conferences-and-exhibitions/photonics-europe/programme">https://spie.org/conferences-and-exhibitions/photonics-europe/programme</a>
<b>EMBO Workshop, Building Networks: Engineering in Vascular Biology</b>	09.-11.05.2022	Barcelona	AAU: Cecilia Sahlgren	Presentation	<a href="https://www.embl.org/about/info/course-and-conference-office/events/evb22-01">https://www.embl.org/about/info/course-and-conference-office/events/evb22-01</a>
<b>Biochip Berlin, International Forum on BioChips and BioChip Solutions</b>	10.-11.05.2022	Berlin	AMI: Kristin Aldag	Attendance, networking with exhibitors	<a href="https://biochip-berlin.de/">https://biochip-berlin.de/</a>
<b>Biocity Symposium 2022, Solution is in Immunity</b>	25-26.05.2022	Turku, Finland	AAU: Marjaana Parikainen	Poster presentation	<a href="https://biocityturku.fi/biocity-symposium/">https://biocityturku.fi/biocity-symposium/</a>

## Tumor-LN-oC

<b>ICPPP21 International Conference on Photoacoustic and Photothermal Phenomena</b>	19.-24.06.2022	Bled, Slovenia	TUW: Elisabeth Holub	Poster presentation	<a href="https://indico.ung.si/event/5/">https://indico.ung.si/event/5/</a>
<b>IndTech2022 – Industrial technologies conference</b>	27.-29.06.2022	Grenoble	AMI: Kristin Aldag ICCS: Ioanna Zergioti	Distribution of leaflets	<a href="https://indtech2022.eu/">https://indtech2022.eu/</a>
<b>10th International Symposium and Scientific Meeting on Alagille Syndrome (ALGS meeting)</b>	June 16-19th 2022	Cincinnati, Ohio, USA + online	AAU: Cecilia Sahlgren	Presentatio	<a href="https://www.eventbrite.com/e/10th-international-symposium-and-scientific-meeting-on-alagille-syndrome-registration-252581567267">https://www.eventbrite.com/e/10th-international-symposium-and-scientific-meeting-on-alagille-syndrome-registration-252581567267</a>
<b>European Organ-on-chip meeting 2022</b>	04.-05.07.2022	Grenoble	ICCS: Marianneza Chatzipetrou, TU/e: Ye Wang	Poster presentation	<a href="https://euroocs.eu/annual-meeting/">https://euroocs.eu/annual-meeting/</a>
<b>Nanotextology I3D22</b>	05.-08.07.2022	Thessaloniki	PhosPrint: Evina Elezoglou	Presentation	<a href="https://www.nanotextology.com/images/stories/food/I3D22_PROGRAM.pdf">https://www.nanotextology.com/images/stories/food/I3D22_PROGRAM.pdf</a>
<b>The Next Gen Organ-on-Chip &amp; Organoids workshop</b>	23.-24.08.2022	Geneva	ICCS, ELV	Attendance, networking	<a href="https://www.csem.ch/page.aspx?pid=155967">https://www.csem.ch/page.aspx?pid=155967</a>
<b>"Cell la Vie"</b>	21.-23.09.2022	Paris	ELV	Booth	<a href="https://sbcf.fr/en/event/cell-la-vie-2">https://sbcf.fr/en/event/cell-la-vie-2</a>
<b>Webinar Organized by Precisionary Instruments Inc</b>	20.09.2022	Online	BRFAA, Katerina	Presentation	<a href="https://precisionary.com/support/product-support-menu/webinars/">https://precisionary.com/support/product-support-menu/webinars/</a>
<b>SciX 2022</b>	02.-07.10.2022	Covington, USA	TUW: Georg Ramer		<a href="https://scixconference.org/">https://scixconference.org/</a>
<b>Enhpathy MCSA-ITN</b>	03.-07.10.2022	Santander, Spain	ELV: Julia Sepulveda		<a href="https://www.enhpathy.eu/wp-content/uploads/2022/09/Enhpathy-Event-V-Program.pdf">https://www.enhpathy.eu/wp-content/uploads/2022/09/Enhpathy-Event-V-Program.pdf</a>
<b>2nd Regenerative Medicine Workshop</b>	12.10.2022	Prague	ICCS: Ioanna Zergioti AMI: Kristin Aldag	Presentation, round table	<a href="https://amires.eu/2nd-regenerative-medicine-workshop-october-12th-2022-prague-registration-is-open">https://amires.eu/2nd-regenerative-medicine-workshop-october-12th-2022-prague-registration-is-open</a>
<b>Aurum Day</b>	21.10.2022	Turku, Finland	AAU: KaiLan Lin	Poster presentation	
<b>Nordic organoid/OoC zoom pitching event</b>	27.10.2022	online	AAU: Kai-Lan Lin	Presentation	<a href="https://nordic-organ-on-a-chip.eu/">https://nordic-organ-on-a-chip.eu/</a>
<b>ÅAU Bioseminar</b>	29.10.2022	Turku, Finland	AAU: Diosáγγελos Soto Véliz		
<b>Cancer Biology GIDP Seminar Series</b>	21.11.2022	Arizona, USA (online)	AAU: Cecilia Sahlgren		<a href="https://healthsciences.arizona.edu/connect/calendar/2022/cancer-biology-gidp-seminar-series-21">https://healthsciences.arizona.edu/connect/calendar/2022/cancer-biology-gidp-seminar-series-21</a>

## Tumor-LN-oC

2023					
<b>9th COST Action CardioRNA</b>	22.-24.02.2023	Nicosia Cyprus	ICCS: Ioanna Zergioti	Oral Presentation	<a href="https://www.cost.eu/actions/CA17129/">https://www.cost.eu/actions/CA17129/</a>
<b>EU FINANCE DAYS 2023</b>	30.03.2023	Athens, Greece	PhosPrint: Ioanna Zergioti	Presentation	<a href="https://greece.representation.ec.europa.eu/news/i-eyropaiki-epitropi-di-organonei-tin-imerida-eu-finance-days-2023-tin-pempti-30-martioy-2023-stin-2023-03-23-el">https://greece.representation.ec.europa.eu/news/i-eyropaiki-epitropi-di-organonei-tin-imerida-eu-finance-days-2023-tin-pempti-30-martioy-2023-stin-2023-03-23-el</a>
<b>MIT Global Startup Workshop (MIT GSW) 2023</b>	30.-31.03.2023	Athens, Greece	PhosPrint; I.Zergioti, A. Klinakis; M. Pallidou; M. Dimadi	Presentation	<a href="https://gsw.mit.edu/2023/">https://gsw.mit.edu/2023/</a>
<b>Anakon 2023</b>	11-14.04.2023	Vienna, Austria	TUW: Elisabeth Holub, Georg Ramer	Poster + oral presentation	<a href="https://www.anakon2023.at/">https://www.anakon2023.at/</a>

Table 7: Participation in events and conferences confirmed for 2023 and 2024

Conference Name	Date	Location	Responsible Partner	Tumor-LN-oC participation	Link
<b>3rd Regenerative medicine workshop</b>	01.06.2023	Prague, Czech Republic	PhosPrint; M. Pallidou, I. Theochari	Presentation	<a href="https://www.amires.eu/regmed2023-from-idea-to-patient-june-1st-prague/">https://www.amires.eu/regmed2023-from-idea-to-patient-june-1st-prague/</a>
<b>Life at the periphery: mechanobiology of the cell surface</b>	12.-15.06.2023	Heidelberg, Germany + virtual	AAU; Cecilia Sahlgren, KaiLan Lin	Attendance	<a href="https://www.embl.org/about/info/course-and-conference-office/events/ees23-05/">https://www.embl.org/about/info/course-and-conference-office/events/ees23-05/</a>
<b>18th conference of the Hellenic Society of Pathological Anatomy</b>	21.-24.06.2023	Volos, Greece	BRFAA	Poster	<a href="https://medicalcongress.gr/iatriko-synedrio/">https://medicalcongress.gr/iatriko-synedrio/</a>
<b>32nd BioCity Symposium: Sculpting Tissues – cells, matrix and forces</b>	24.-25.10.2023	Turku, Finland	AAU: Cecilia Sahlgren	Presentation	<a href="https://biocityturku.fi/biocity-symposium/">https://biocityturku.fi/biocity-symposium/</a>
<b>EMBL Conference, The new cardiobiology</b>	20.-23.02.2024	Heidelberg, Germany	AAU: Cecilia Sahlgren	Presentation	<a href="https://www.embl.org/about/info/course-and-conference-office/events/ncb24-01/">https://www.embl.org/about/info/course-and-conference-office/events/ncb24-01/</a>
<b>Gordon Conference, Mechanisms of Notch Signaling in Health and Disease</b>	14.-19.07.2024	Lewinston, ME, USA	AAU: Cecilia Sahlgren	Presentation	<a href="https://www.grc.org/notch-signaling-in-development-regeneration-and-disease-conference/2024/">https://www.grc.org/notch-signaling-in-development-regeneration-and-disease-conference/2024/</a>

### 3.4. Scientific Publications

As of M24, several technical and scientific publications related to Tumor-LN-oC have been published (see Table 8). At least one further publication regarding the cilia driven flow is currently under preparation by TU/e.

Table 8: Overview of Tumor-LN-oC scientific publications

Scientific Publication	Title	Author	DOI	Publication Date
Biosensors	Bioprinting on Organ-on-Chip: Development and Applications	ICCS, PhosPrint: Maria Anna Chliara, Evina Elezoglou, Ioanna Zergioti	<a href="https://doi.org/10.3390/bios12121135">10.3390/bios12121135</a>	06.12.2022
Smart Medicine	Organ-on-a-chip technologies for biomedical research and drug development: A focus on the vasculature	AAU: Diosangeles Soto Veliz, Kai-Lan Lin, Cecilia Sahlgren	<a href="https://doi.org/10.1002/SMMD.20220030">10.1002/SMMD.20220030</a>	24.02.2023
Advanced Chemical Microscopy for Life Science and Translational Medicine 2023 (SPIE)	Image processing as basis for chemometrics in photothermal atomic force microscopy infrared imaging	TUW: Georg Ramer, A. Catarina V. D. dos Santos, Yide Zhang, Ufuk Yilmaz, Bernhard Lendl	<a href="https://doi.org/10.1117/12.2651424">10.1117/12.2651424</a>	17.03.2023

During project meetings, several team members have pointed out that in biomedical research, it takes a while until publishable results are achieved. In addition, intellectual property-considerations are not yet finalised and publication of some results might be postponed until this is clarified.

In line with the DoA and dissemination strategy, open-access publications is chosen wherever possible. All open-access articles will be linked on the Tumor-LN-oC website as well as published to the community on Zenodo: <https://zenodo.org/communities/tumor-ln-oc/>. Zenodo was created within the [OpenAIRE](#) project, commissioned by the EC to support open access and open data movements in Europe by providing a catch-all repository for EC funded research and hosted securely by CERN.

The screenshot shows the Zenodo interface for the 'Tumor-LN-oC' community. At the top, there is a search bar and navigation links for 'Upload' and 'Communities'. The community title is 'Tumor-LN-oC - Tumor and Lymph Node on Chip for cancer studies'. Below this, the 'Recent uploads' section lists two articles:

- Bioprinting on Organ-on-Chip: Development and Applications** (December 6, 2022): Authors Maria Anna Chliara, Evina Elezoglou, and Ioanna Zergioti. Published in *Biosensors*, vol. 12, issue 12, p. 1135.
- Organ-on-a-chip technologies for biomedical research and drug development: A focus on the vasculature** (February 24, 2023): Authors Diosangeles Soto Veliz, Kai-Lan Lin, and Cecilia Sahlgren. Published in *Smart Medicine*.

A 'New upload' button is located on the right side of the page. The community logo features the letters 'TUOR' with 'LN-oC' below it.

Figure 21: Tumor-LN-oC community on Zenodo

According to article 8.4.2 of the Consortium Agreement (“Dissemination of Results”), during the Project and for a period of 1 year after the end of the Project, the dissemination of any material and/or own results by one or several partners including, but not restricted to, publications and presentations, shall be governed by the procedure of Article 29.1 of the Grant Agreement subject to the provisions outlined in Figure 22. In practice, this means that all intended publications are shared with other partners prior to submission who have a chance to voice any objections.




Figure 22: Procedure outlined in article 8.4.2 of the consortium agreement

### 3.5. Clustering and engagement with other projects

As encouraged by the project officer, contact was sought with Tumor-LN-oC “sister projects” which were funded under the same call for proposals, H2020-NMBP-TR-IND-2020-twostage. Successful co-operation was established with two out the three projects:

Table 9: Clustering with other EU project

Project Acronym + Website	Coordinator	Status of cooperation
<b>Gutvibrations</b> <a href="https://gutvibrations.org/">https://gutvibrations.org/</a>	<b>Dasja Pajkrt</b> Amsterdam UMC	Initial meeting 23.06.2022 Cooperation established
<b>EMAPS-Cardio</b> <a href="https://emaps-cardio.eu/">https://emaps-cardio.eu/</a>	<b>Christian Bergaud</b> Laboratory for Analysis and Architecture of Systems	Initial Meeting 16.06.2022 Cooperation established
<b>Flamingo</b> <a href="https://flamingo-joc.eu/">https://flamingo-joc.eu/</a>	<b>Prof. Annalisa Chiocchetti</b> Università del Piemonte Orientale	Several emails sent in order to set up an initial meeting, unfortunately no reply yet, follow-up request will be sent

Cooperation mainly consist in progress updates and sharing of challenges, sharing of news or events on request, as well as potential future joint organisation and/or participation in events. The project coordinator and dissemination manager will continue to be in touch with these projects and proactively identify and further EU-funded projects or related initiatives

#### **4. Review of project dissemination strategy**

The project dissemination strategy was outlined in D16.1. No significant update is considered necessary at this time. Considerations regarding target audience still apply. Upon conclusion of T17.1, the implementation and coordination of dissemination activities will continue in task T18.1.

#### **5. Conclusions**

This Deliverable reports on the dissemination activities carried out by Tumor-LN-oC partners during the project duration and in particular between M6 (establishment of dissemination strategy) and M24.

The dissemination manager role was established and awarded to Kristin Aldag from AMIRES. A dedicated project website and selected social medial channels inform about the project and are regularly updated with any news. Three scientific publications have been published and more are under preparation. Tumor-LN-oC promotional materials have been created to raise awareness and inform the general public and identified target audiences about the Tumor-LN-oC project and its development. These materials will be extensively used by Tumor-LN-oC partners during conferences, industry fairs, future workshops, and other occasions. Partners have presented the project at over 20 events and conferences. Clustering with related project was initiated. All dissemination activities are being tracked and reported by the dissemination manager.

#### **6. Degree of Progress**

This deliverable is 100% complete and concludes the task 17.1.

#### **7. Dissemination level**

This Deliverable D17.1 is public and will be made available to download on the project's website.